Lysine based compounds

Details Lysine based compounds Lysine based compounds

2008-06-17

2008-06-17

Davis, Zinna N. (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C544S148000, C544S159000, C544S406000, C546S316000, C546S323000, C548S333500, C548S537000, C549S438000, C549S487000, C560S010000, C560S013000, C562S427000, C562S430000, C564S085000

Reexamination Certificate

active

07388008

ABSTRACT:
The present invention provides lysine based compounds of the formula;and when the compound of formula I comprises an amino group, pharmaceutically acceptable ammonium salts thereof, wherein R1may be, for example, (HO)2P(O)—, (NaO)2P(O)—, alkyl-CO— or cycloalkyl-CO—, wherein X may be, for example, F, Cl, and Br, and wherein R2and R3are as defined herein.

REFERENCES:
patent: 5013861 (1991-05-01), Weller, III et al.
patent: 5527829 (1996-06-01), Kalish
patent: 5614522 (1997-03-01), Talley et al.
patent: 5714605 (1998-02-01), Vazquez et al.
patent: 5776718 (1998-07-01), Palmer et al.
patent: 5965588 (1999-10-01), Vazquez et al.
patent: 6022994 (2000-02-01), Vazquez et al.
patent: 6159995 (2000-12-01), Thorwart et al.
patent: 6384036 (2002-05-01), Freskos et al.
patent: 6436989 (2002-08-01), Hale et al.
patent: 6506786 (2003-01-01), Stranix et al.
patent: 6528532 (2003-03-01), Stranix et al.
patent: 6656965 (2003-06-01), Stranix et al.
patent: 6608100 (2003-08-01), Stranix et al.
patent: 6610689 (2003-08-01), Stranix et al.
patent: 6632816 (2003-10-01), Stranix et al.
patent: 6677367 (2004-01-01), Stranix et al.
patent: 6703403 (2004-03-01), Norbeck et al.
patent: 2006/0025592 (2006-02-01), Stranix et al.
patent: 2006/0287316 (2006-12-01), Wu et al.
patent: 2316218 (1999-07-01), None
patent: 0532466 (1993-03-01), None
patent: WO-92/06998 (1992-04-01), None
patent: WO-95/24385 (1995-09-01), None
patent: WO-97/27180 (1997-07-01), None
patent: WO-98/31664 (1998-07-01), None
patent: WO-99/55687 (1999-11-01), None
patent: WO-01/68593 (2001-09-01), None
patent: WO 02/064551 (2002-08-01), None
patent: WO-2003/074467 (2003-09-01), None
patent: WO-2004/054586 (2004-07-01), None
patent: WO-2004/086764 (2004-07-01), None
patent: WO-2005/066131 (2005-07-01), None
patent: WO-2006/012725 (2006-02-01), None
patent: WO-2006/114001 (2006-11-01), None
patent: WO-2007/062526 (2007-06-01), None
Matayoshi, et al., Science, 247: p. 954-958, 1990.
Japour, et al., Antimicrobial Agents and Chemotherapy, 37: p. 1095-1101. 1993.
Pauwels, et al., J. Virological Methods, 20: p. 309-321, 1988.
Meek et al., Letters to Nature, vol. 343: p. 90-92, 1990.
Bouzide, Abderrahim et al., Lysine derivatives as a potent HIV protease inhibitors, Discovery, synthesis and structure-activity relationship studies, Med. Chem. Lett. 15(2005) 1509-1513.
Ettmayer, Peter et al., Lessons Learned from Marketed and Investigational Prodrugs, Journal of Medicinal Chemistry, 2004, 47(10):2393-2404.
Vierling, Pierre and Greiner, Jacques, Prodrugs of HIV Protease Inhibitors, Current Pharmaceutical Design, 2003, 9(22):1755-1770.
T.G. Hamill et al: J. Labelled Compd. Radiopharm., vol. 42, No. 6, 1999, pp. 605-609, XP000926587.
T.W. Greene and P. G. M. Wuts, Protective groups in Organic Synthesis, John Wiley & Sons, Inc. 1981.
A. Andrade et al. “HIV-Related Drug Metabolism and Cytochrome P450 Enzymes.” AIDS Clin. Care, vol. 12, No. 11, 2000, pp. 91-95.
Organic Synthesis, 3rd Edition, pp. 520-521 (T. W. Greene and P. G. M. Wuts (John Wiley & Sons, Inc. 1999).
A.M. El-Naggar et al: Acta Pharm. Jugosl., vol. 33, No. 2, 1983, pp. 103-110, XP000926585.
A.M. El-Naggar et al: Pol. J. Chem., vol 52, No. 3, 1978, pp. 637-642, XP000926586.
Anderson et al. in the J. Am. Chem. Soc. 1964, 1839.
T. Lescrinier et al: J. Pept. Res., vol. 49, No. 2, 1997, pp. 183-189, XP000679594.
Bukrinsky et al., Proc. Nat. Acad. Sci. USA vol. 89, pp. 6580-6584 (1992).
Calogeropoulou et al. “Strategies in the design of prodrugs on anti-HIV agents” Current Topics in Medicinal Chemistry, 2003, 3, 1467-1495.
Chemical Abstracts, vol. 46, No. 13, Jul. 10, 1952. N. Izumiya: The Walden inversion of amino acids. II. “The Walden inversion ofNδ-benzoyl-L-omithine.” Column 6593.
Chemical Abstracts, vol. 46, No. 13, Jul. 10, 1952. N. Izumiya: The Walden inversion of amino acids. III. “Nε-benzoyl-L-Iysine.” Column 6593.
Chemical Abstracts, vol. 46, No. 13, Jul. 10, 1952. N. Izumiya: The Walden inversion of amino acids. IV. “Synthesis of Nα-methyl-L-ornithine and Nα-methyl derivative of arginine.” Column 6593.
Chemical Abstracts, vol. 62, No. 2, Jan. 18, 1965. P. Hermann et al: “Peptide synthesis with S-(β-aminoethyl)-L-cysteine”. Column 1740.
Sakai, H al., J. virol. vol. 67, pp. 1169-1174 (1993).
D. J. Kempf et al. “Pharmacokinetic Enhancement of Inhibitors of the Human Immunodeficiency Virus Protease by Coadministration with Ritonavir.” Antimicr. Agents Chem., vol. 41, No. 3, Mar. 1997, pp. 654-660.
Dankwardt et al, Bioorganic and Medicinal Chemistry Letters, vol. 12, pp. 1233-1235, Jan. 2002.
D.T. Elmore et al: “Amino Acids and Peptides”. Collect. Czech. Chem. Commun., vol. 34, No. 2, 1969, pp. 630-634.
J. Kolc: “Amino Acids and Peptides”. Collect. Czech. Chem. Commun., vol. 34, No. 2, 1969, pp. 630-634.
S.P. Solinas et al: “The Oxidative Deamination of . . . Acid Oxidase”. Physiol. Chem. Phys. Med. NMR, vol. 25, No. 4, 1993, pp. 281-285.
Chemical Abstracts, vol. 123, No. 7, Aug. 14, 1995, Abstract No. 83099.
Protective Groups in Organic Synthesis, Collective vol. II, pp. 258-263.
G. Karup et al: Int. J. Pept. Protein res., vol. 32, No. 5, 1988, pp. 331-343, XP000926584.
G. Kottirsch et al: Bioorg. Med. Chem. Lett., vol. 7, No. 6, 1997, pp. 727-732, XP004136118.
Gallay et al., Cell, vol. 80, pp. 379-388 (1995).
Garrity, et al., 1993, Tetrahedron Letters, 34(35), 5531-4.
Goff S. P. J. Acq. Imm. Defic. Syndr., vol. 3 pp. 817-831 (1990).
Haseltine W. A. Faseb J. vol. 5 2349-2360 (1991).
I. Schön et al: synthesis, No. 4, 1986, pp. 303-305, XP002182716.
J. Hlavacek et al: Collect. Czech. Chem. Commun., vol. 53, No. 11A, 1988, pp. 2473-2494, XP001002995.
J. Org. Chem. 44, 4841 (1979).
J.Leclerc et al: Can. J. Chem., vol. 46, No. 7, 1968, pp. 1047-1051, XP000926722.
J.M. Treluyer et al. “Oxidative metabolism of Amprenavir in the human liver. Effect of the CYP3A Maturation.” Drug Metab. Disp., vol. 31, No. 3, 20003, pp. 275-281.
Lasky L. A. et al., Cell vol. 50, pp. 975-985 (1987).
M. Maeda et al: Chem. Pharm. Bull., vol. 33, No. 5, 1985, pp. 2137-2141, XP001010687.
M.E. Fitzsimmons et al. “Selective biotransformation of the human immunodefiency virus protease inhibitor Saquinavir by human small intestinal Cytochrome P4503A4.” Drug metab. Disp., vol. 25, No. 2, 1997, pp. 256-266.
Poduska, et al., 1965, Collection Czech. Chem. Commun., 30(7), 2410-2433.

Affiliated with

Also associated with

Rating

Lysine based compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Lysine based compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lysine based compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2802246